[go: up one dir, main page]

WO2020032379A1 - Composition pour la prévention ou le traitement du cancer, comprenant un exosome dérivé de macrophages de suppression de cellules apoptotiques - Google Patents

Composition pour la prévention ou le traitement du cancer, comprenant un exosome dérivé de macrophages de suppression de cellules apoptotiques Download PDF

Info

Publication number
WO2020032379A1
WO2020032379A1 PCT/KR2019/007379 KR2019007379W WO2020032379A1 WO 2020032379 A1 WO2020032379 A1 WO 2020032379A1 KR 2019007379 W KR2019007379 W KR 2019007379W WO 2020032379 A1 WO2020032379 A1 WO 2020032379A1
Authority
WO
WIPO (PCT)
Prior art keywords
macrophages
cancer
cells
exosomes
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/007379
Other languages
English (en)
Korean (ko)
Inventor
이지희
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ewha Womans University
Original Assignee
Ewha Womans University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ewha Womans University filed Critical Ewha Womans University
Publication of WO2020032379A1 publication Critical patent/WO2020032379A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Definitions

  • the present invention relates to a composition for preventing or treating cancer, the use thereof, and a method for treating cancer using the same, including apoptosis-derived macrophage-derived exosomes.
  • EMT Epithelial-mesenchymal transition
  • ETM epithelial-mesenchymal transition
  • Cancer is the life-threatening cause of cancer metastasis, and most deaths from cancer are explained by cancer metastasis.
  • the current clinically proven method for treating cancer is surgical surgery, even if the causative cancer is removed, the treatment of the patient becomes difficult by cancer cells that have metastasized to other tissues. Therefore, cancer conquest can be regarded as a fight against cancer metastasis, and much research is currently being conducted on the mechanism of cancer metastasis, but this situation does not lead to the development of a therapeutic agent.
  • exosomes are generically referred to as exosomes produced by fusion of MVB (Multivesicular bodies) with the plasma membrane and microvesicles generated by direct release from the plasma membrane, also called extracellular vesicles (extracellular vesicle).
  • MVB Multivesicular bodies
  • extracellular vesicles extracellular vesicle
  • Exosomes are small vesicles of membrane structure (approximately 30-100 nm in diameter) that are secreted from a variety of cells, and within the cells called multivesicular bodies (MVBs), rather than falling directly off the plasma membrane in an electron microscope study. Originated from specific compartments and released and secreted out of cells was observed. In other words, when fusion occurs between the polycystic body and the plasma membrane, the vesicles are released into the extracellular environment, which is called an exosome.
  • MVBs multivesicular bodies
  • exosomes are made of, but not only red blood cells, but also various immune cells and tumor cells, including B-lymphocytes, T-lymphocytes, dendritic cells, platelets, macrophages, etc. Death cells, stem cells, etc. are also known to produce and secrete exosomes in the living state.
  • exosomes contain a variety of substances having very different characteristics depending on their origin, it is necessary to proceed with research and development on characteristics derived from specific cells.
  • exosomes derived from macrophage exposed to apoptosis cells reach cancer cells, inhibit epithelial-mesenchymal cell conversion in cancer cells, inhibit cancer cell invasion, or prevent or treat cancer.
  • the present invention was completed by confirming the excellent effect.
  • An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of cancer, including exosomes derived from apoptosis-treated macrophages.
  • the present invention provides a pharmaceutical composition for preventing or treating cancer, including exosomes derived from apoptosis-treated macrophages.
  • the apoptotic cells are preferably epithelial cancer cells, and in accordance with a specific embodiment of the present invention, epithelial cancer cells are most preferred.
  • epithelial cancer cells are most preferred.
  • 344SQ cells, A549 cells, MDA-MB-231 cells, COLO320HSR cells, PC3 cells and the like but is not limited thereto.
  • the killed cells are preferably irradiated with UV light for 5 to 30 minutes at a wavelength of 100 to 400 nm, more preferably at 5 to 20 minutes at a wavelength of 150 to 350 nm, more preferably 200 to 300 It is most preferable to irradiate ultraviolet rays for 10 to 15 minutes at a wavelength of nm, but is not limited thereto.
  • the epithelial cancer cells may be incubated for 1 to 5 hours at 30 to 40 °C temperature under 1 to 10% CO 2 conditions in RPMI 1604 medium added with 10% FBS after UV irradiation.
  • the macrophages can be any of mouse and human origin and can be bone marrow-derived macrophage or monocyte-derived macrophages.
  • microglia histiocytes, Hofbauer cells, mesangial cells, Kupffer cells, peritoneal macrophages, alveolar macrophages macrophage, epidermal or dermal macrophages, marginal zone macrophages, metallophilic macrophages, red pulp macrophages, white pulp macrophages) and osteoclasts (osteoclasts).
  • the treatment may mean culturing apoptosis cells and macrophages together. That is, it may be an exosome isolated from the culture obtained by culturing apoptosis cells and macrophages together.
  • the method may be as follows, for example. Incubate in X-VIVO or serum-free DMEM medium for 20-30 hours before stimulating macrophages with apoptosis. According to a specific embodiment of the present invention, it is most preferable to incubate in X-VIVO medium for 24 hours to make the serum-deficient state. To stimulate, the culture medium can be replaced with X-VIVO or serum-free DMEM medium with killed cells. It is preferable to incubate apoptosis cells and macrophages together for 10 to 30 hours after the medium change, more preferably for 15 to 25 hours, and most preferably for 18 to 24 hours.
  • the exosomes are 40-120 nm nanovesicles secreted from cells, including the main histocompatibility complex (MHC) and heat shock protein, which are immunologically important proteins. It induces a strong anti-tumor immune response and includes anti-inflammatory microRNAs (microRNAs) and microRNAs (microRNAs) that regulate the accumulation of collagen. In addition, it is known to play various roles such as binding to other cells and tissues to deliver membrane components, proteins, RNA.
  • MHC main histocompatibility complex
  • heat shock protein which are immunologically important proteins. It induces a strong anti-tumor immune response and includes anti-inflammatory microRNAs (microRNAs) and microRNAs (microRNAs) that regulate the accumulation of collagen.
  • microRNAs anti-inflammatory microRNAs
  • microRNAs microRNAs
  • microRNAs microRNAs
  • centrifugation for example, in a culture medium, centrifugation, ultrafast centrifugation, filtration by filter, gel filtration chromatography, pre-flow electrophoresis, capillary electrophoresis, using polymer Separation may be carried out using a method such as separation and a combination thereof, preferably centrifugation / supercentrifugation.
  • centrifugation / supercentrifugation centrifugation may be performed sequentially at 100 to 300,000 g, preferably 150 to 150,000 g, to remove cell debris, non-exosome fraction, and dead cells.
  • the pharmaceutical composition of the present invention has an excellent effect on the prevention or treatment of cancer.
  • exosomes are uptake into cancer cells, inhibit EMT action and inhibit Akt / p38 signaling cascade to inhibit cancer cell infiltration and metastasis. Accordingly, it has an excellent effect on the prevention, treatment and suppression of metastasis of cancer. Furthermore, the use of the exosomes according to the present invention has the advantage of being safe for human body and excellent effect even with a small amount of administration compared to the direct administration of apoptosis cells, macrophages or control medium.
  • exosomes according to the present invention while containing a variety of components, in particular, PTEN protein inhibits the EMT action of cancer and shows an excellent effect on cancer metastasis through Akt / p38 signaling cascade inhibition.
  • the present invention is characterized by inhibiting EMT (epithelial-mesenchymal transition), characterized in that the early stage of cancer metastasis, such as cancer cell migration and infiltration due to the EMT inhibitory action.
  • EMT is a phenomenon in which epithelial cells are converted into mesenchymal cells, and cell adhesion substances such as E-cadherin are lost and morphological changes are induced in the process of cancer formation and metastasis, causing EMT to change the epithelial tumor cells. It is known to play various roles in the transition process.
  • TGF- ⁇ 1 was treated to induce EMT of cells and inhibited it through exosomes.
  • the cancer may be selected from various carcinomas that are not limited to a specific carcinoma.
  • it may be any one selected from the group consisting of lung cancer, breast cancer, prostate cancer and colon cancer.
  • the exosomes according to the present invention included in the pharmaceutical composition as an active ingredient, but is not limited thereto, at a concentration of 1 to 200 ⁇ g / ml, or at a concentration of 5 to 150 ⁇ g / ml, or 10 It may be included in the pharmaceutical composition at a concentration of from 100 ⁇ g / ml to the subject.
  • the pharmaceutical composition according to the present invention can be used alone as an anticancer therapy.
  • composition according to the present invention may be used simultaneously, separately or sequentially with radiation or an anticancer agent, if necessary.
  • the pharmaceutical composition may be administered as a separate therapeutic agent, or may be administered in combination with radiation or other therapeutic agents, and may be administered sequentially or simultaneously with conventional radiation or anticancer therapeutic agents.
  • the pharmaceutical composition may include a pharmaceutically effective amount of exosomes alone or may include one or more pharmaceutically acceptable carriers, excipients or diluents.
  • a pharmaceutically effective amount herein means an amount sufficient to prevent, ameliorate and treat the symptoms of cancer.
  • the pharmaceutically effective amount of the exosomes according to the present invention may be appropriately changed depending on the degree of symptoms of cancer, the age, weight, health condition, sex, route of administration and duration of treatment of the patient.
  • a suitable dosage may be 0.0001 to 100 mg / kg body weight.
  • the term "pharmaceutically acceptable” refers to a composition which, when administered physiologically and humanly, does not normally cause an allergic reaction such as gastrointestinal disorders, dizziness or the like.
  • carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers and preservatives may be further included.
  • the pharmaceutical composition for preventing or treating cancer of the present invention may be administered in a unit dosage form suitable for administration in the body of a patient according to a conventional method in the pharmaceutical field.
  • Formulations suitable for this purpose include parenteral injectables such as injectable ampoules, injectables such as infusion bags, sprays such as aerosol preparations and the like.
  • the injection ampoule may be mixed with the injection solution immediately before use, and as the injection solution, physiological saline, glucose, mannitol, and Ringer's solution may be used.
  • the infusion bag may also be made of polyvinyl chloride or polyethylene and may be Baxter, Becton-Dickinson, Medcep, National Hospital Products, or Terumo.
  • An injection bag of a cinnamon yarn can be illustrated.
  • the pharmaceutical composition may contain one or more pharmaceutically acceptable inert carriers, for example, preservatives, analgesics, solubilizers or stabilizers in the case of injections, in addition to the active ingredient.
  • pharmaceutically acceptable inert carriers for example, preservatives, analgesics, solubilizers or stabilizers in the case of injections, in addition to the active ingredient.
  • Bases excipients, lubricants or preservatives and the like.
  • composition or pharmaceutical formulation of the present invention may be administered to mammals such as rats, mice, livestock, humans, etc. by various routes, such as parenteral or oral, and the administration method may be any method commonly used in the art. It can be administered by.
  • the present invention may be administered by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection and the like.
  • the method of administration is not limited thereto, but the exosomes are administered intravenously (Intravenous injection), administered into the subject's lungs or organs (Topical administration), or by inhalation. Can be.
  • the exosomes can be administered using a nebulizer, it can be administered using an endotracheal tube.
  • the subject means all animals including humans having developed the resistant cancer, and the cancer may be treated by administering the composition of the present invention to the subject.
  • Treatment in the present invention means any action by which the cancer is improved or beneficially altered by administering the pharmaceutical composition of the present invention.
  • Administration in the present invention refers to the action of introducing the pharmaceutical composition of the present invention to a subject by any suitable method, the route of administration may be administered via various routes orally or parenterally as long as the target tissue can be reached.
  • the present invention also provides a pharmaceutical composition for inhibiting metastasis of cancer, including an exosome derived from apoptotic cell treated macrophages.
  • the composition according to the present invention is uptake into cancer cells (uptake), inhibits EMT action and inhibits Akt / p38 signaling cascade to inhibit the penetration and metastasis of cancer cells. Accordingly, it can be used as a composition for inhibiting metastasis of cancer.
  • the present invention provides a method of treating cancer comprising administering to a subject an exosome derived from apoptosis-treated macrophages.
  • the subject refers to an animal and may be a mammal, which may typically have a beneficial effect with treatment with exosomes derived from the apoptosis-treated macrophages of the invention.
  • Preferred examples of such subjects may include primates, such as humans.
  • such subjects may include all subjects having cancer symptoms or at risk of having such symptoms.
  • a method for inhibiting metastasis of cancer comprising administering to a subject an exosome derived from apoptosis-treated macrophages.
  • the invention also provides the use of exosomes derived from apoptotic treated macrophages in the manufacture of a medicament for the treatment of cancer.
  • compositions comprising exosomes derived from killed cell treated macrophages for use in the treatment of cancer.
  • the invention also provides the use of exosomes derived from apoptotic cell treated macrophages for the treatment of cancer.
  • the invention also provides a method for separating exosomes from apoptosis treated macrophages.
  • the method for separating exosomes from killed cell treated macrophages according to the present invention may comprise the following steps:
  • step (b) separating the supernatant from the culture solution of step (a);
  • step (c) separating the exosome from the supernatant of step (b).
  • the culturing of the apoptotic cells and the macrophages is carried out for 10-30 hours, preferably 15-25 hours, for example, in X-VIVO or serum-free DMEM medium containing the killed cells. More preferably 18 to 24 hours. Through such culture, exosomes can be contained in a large amount in the gastric culture.
  • the supernatant is separated from the culture solution by separating the supernatant from the culture solution by a conventional supernatant separation method.
  • a conventional supernatant separation method For example, it can be separated under conventional supernatant separation centrifugation conditions.
  • the step of separating the exosome from the supernatant of the step (b) may use a conventional known exosome separation method.
  • a conventional known exosome separation method for example, centrifugation, ultra-fast centrifugation, filtration by filter, gel filtration chromatography, pre-flow electrophoresis, capillary electrophoresis, separation using a polymer, and the like, and combinations thereof may be used.
  • centrifugation / supercentrifugation may be performed sequentially at 100 to 300,000 g, preferably 150 to 150,000 g, to remove cell debris, non-exosome fraction, and dead cells.
  • the pharmaceutical composition of the present invention is absorbed into cancer cells and inhibits epithelial-mesenchymal cell conversion in cancer cells and down-regulates Akt / p38 signal cascade, thereby inhibiting cancer cell infiltration, thereby having an excellent effect on preventing or treating cancer and inhibiting metastasis of cancer. have.
  • Figure 2 shows the results of confirming the uptake with cancer cells analyzed after exosomes and 344SQ or A549 cells according to the present invention, GFP fluorescence through confocal microscopy.
  • Figure 3 shows the results of confirming the uptake of exosomes by incubating the lysates from 344SQ or A549 cells after incubation with exosomes collected from overexpressing GFP-PTEN human macrophage line.
  • Figure 5 shows the results of normal acini of 344SQ grown on 3D Matrigel containing exosomes and stained with anti-b-catenin (shown in light gray on green, black and white drawings) and DAPI.
  • Figure 6 shows the results confirming that the level of increased PTEN in 344SQ cells is due to the PTEN secreted from the exosomes and not the expression of PTEN through stimulation of the cells themselves by specific molecules of the exosomes.
  • 7A is a TEM image of exosomes isolated from the conditioned medium of ApoSQ-stimulated RAW cells either pretreated or untreated with 20 ⁇ GW4869. Scale bar represents 20 mm.
  • FIG. 7B shows size distribution analysis of exosomes from conditioned media of ApoSQ-stimulated RAW cells pretreated with GW4869 or pretreated with vehicle (2% DMSO in saline).
  • the horizontal axis represents particle size (nm) and the vertical axis represents particle concentration (x106 particles / ml).
  • the bar above the solid line (black dot) represents s.e.m and the value represents the mode or mean size ⁇ s.e.m from three independent experiments.
  • FIG. 8 shows qPCR analysis of PTEN mRNA in 344SQ cells 12 hours after treatment with exosomes isolated from RAW conditioned medium with or without apoptotic 344SQ cells (ExoApoSQ CM). The experiment shows the results of three replicates (mean ⁇ s.e.m.).
  • GFP-PTEN overexpressing macrophages were prepared and used. Standard lentiviral transduction was performed to prepare GFP-PTEN overexpressing macrophages.
  • HEK293T cells were infected with pLV-EGFP-PTEN, packaging (psPAX2) and envelope (pCMV-VSV-G) vectors using TransIT ® -LT1 Transfection Reagent (MIR 2300, Mirus Bio, Madison, WI, USA) and incubated overnight It was. Reagents were replaced with fresh medium for lentiviral transduction and virus supernatants were collected every 24 hours after transfection.
  • Human macrophages (hM ⁇ ) differentiated from THP-1 monocytes were prepared by exposing the supernatant with 8 ⁇ g / ml polybrene for 4 hours every virus collection time and selecting infected cells using 1 ⁇ g / ml containing puromycin-containing medium. It was. Through this, GFP-PTEN overexpressing macrophages were prepared.
  • 344SQ cells or A549 cells were irradiated with UV light at 254 nm for 10 minutes, followed by 37 ° C., 5% CO 2 conditions in RPMI-1640 medium supplemented with 10% FBS. Incubated for 2 hours under The cell nuclear morphology evaluation using the Wright-Giemsa staining sample and the microscope confirmed that approximately 70-80% of cell death occurred in the UV-irradiated cells. Lysed necrotic epithelial cancer cells were obtained in several freeze-thaw cycles.
  • Serum-starved conditions were provided under X-VIVO 10 medium (04-380Q, Lonza) for 24 hours before stimulating gastric GFP-PTEN overexpressing macrophages.
  • the culture medium was replaced with X-VIVO 10 medium containing killed or necrotic cells (apoptotic 344SQ or apoptotic A549 cells, 1.5 ⁇ 10 6 cells / ml).
  • the supernatant was obtained by centrifugation and used as a conditioned medium for exosome purification.
  • the supernatant obtained above was subjected to sequential centrifugation of 200 g, 20,000 g, and 100,000 g to remove dead cells, cell debris, and non-exosome fractions. Wash exosome pellets with ice-cold PBS containing protease inhibitors and allow ultracentrifugation (Optima L-100K, Beckman Coulter Inc., Brea, Calif., USA) for 70 minutes at 100,000 g to remove contaminated protein. was repeated. Exosomal pellets were suspended in RIPA buffer containing protease inhibitors to prepare exosomes.
  • the prepared GFP-PTEN overexpressing THP-1 macrophages of Example 1 were grown in a 150 mm culture dish until reaching 70% confluency. Then, the cells were stimulated with dead A549 cells for 24 hours, and the conditioned medium was sequentially centrifuged. Exosome pellets were suspended in 200 ⁇ l serum free RPMI to prepare exosomes. The cells (A549 or 344SQ with 1 ⁇ 10 5 cells for confocal microscopy or 3 ⁇ 10 5 cells for western blot) were then exposed to 50 ⁇ l of purified exosomes for 24 hours.
  • GFP-PTEN in cells was visualized via direct fluorescence and also identified as anti-GFP using total cell lysate. The results are shown in FIG. As confirmed in Figure 2, uptake of exosome GFP-PTEN was confirmed.
  • CM of Example 1 conditional medium containing macrophages exposed to apoptotic cells
  • CM of Example 1 conditional medium containing macrophages exposed to apoptotic cells
  • Purified exosomes from or exosomes purified from macrophages not exposed to killer cells were treated with TGF- ⁇ 1 and 344SQ cells.
  • FIG. 4A shows the results of confirming changes in protein expression of the EMT signal. As confirmed in FIG. 4a, the exosomes according to Example 1 suppressed the EMT effect by down-regulating the EMT signal.
  • Single cell suspensions containing 5,000 cells / well were placed in solidified Growth Factor Reduced Matrigel (Corning Inc) in 8 well plates.
  • Cells in RPMI1640 containing 10% FBS and 2% Matrigel were cultured and the cultures were exchanged every two or three days for one week.
  • cells were treated with conditioned medium containing TGF- ⁇ 1 (10 ng / ml) and 2% Matrigel, and then photographed with a clipse TE-300 microscope (Nikon) while incubating for 12 hours.
  • exosomes purified from ApoSQ-exposed CM conditional medium containing macrophages exposed to apoptosis cells
  • exosomes purified from macrophages not exposed to apoptosis cells with or without TGF- ⁇ 1 344SQ cells were treated.
  • 344SQ cells were fixed with 4% PFA solution for 8 minutes at room temperature.
  • formalin fixation was performed at room temperature for 30 minutes and IF-Wash buffer (0.05% NaN 3 in PBS, 0.1% BSA, 0.2% Triton X-100 and 0.05% Tween-20) were used. After fixation, samples were washed three times with washing buffer for 5 minutes each and permeabilized with 0.5% Triton X-100 in PBS at room temperature for 5 minutes.
  • 5% BSA and Mouse IgG Blocking Reagent in PBS were used for ICC and IHC, respectively. All slides stained with antibodies were then mounted with Vectashield Mounting Medium containing DAPI and imaged with a confocal microscope (LSM 800, Carl Zeiss).
  • the test was performed by treating exosomes purified from ApoSQ-stimulated macrophages transfected with siRNAs. Was performed.
  • RAW 264.7 cells were transfected with the two PTEN siRNA or control siRNA sequences in Table 1 below.
  • PTEN (# 1) 5'-CAGGAAUGAACCAUCUACA-3 '(SEQ ID NO: 1) PTEN (# 1) 5'-UGUAGAUGGUUCAUUCCUG-3 '(SEQ ID NO: 2) PTEN (# 2) 5'-CUGAGUAGAAACAAGAGUA-3 '(SEQ ID NO: 3) PTEN (# 2) 5'-UACUCUUGUUUCUACUCAG-3 '(SEQ ID NO: 4)
  • RAW 264.7 cells were transfected with the sequence or control siRNA (SN-1003_AccuTargetTM Negative Control; Bioneer Inc) at a final concentration of 100 nM according to the manufacturer's manual. After transfection overnight, the cells were further cultured for 24 hours and stimulated with apoptotic 344SQ cells.
  • sequence or control siRNA SN-1003_AccuTargetTM Negative Control; Bioneer Inc
  • 6 a shows the result of confirming that PTEN expression was suppressed as a result of transformation.
  • exosome treatment from control siRNA-transfected macrophages followed by PTEN levels increased at 12 and 24 hours in 344SQ cells.
  • treatment of exosomes from PTEN knockdown macrophages did not change PTNE levels.
  • Exosomes secreted from macrophages were isolated by sequential centrifugation, morphologically analyzed by transmission electron microscopy (TEM) and characterized by nanoparticle tracking analysis (NTA) using NanoSight.
  • TEM transmission electron microscopy
  • NTA nanoparticle tracking analysis
  • TEM was performed by the following method. The exosomes divided by 10 ul was fixed with 4% paraformaldehyde at room temperature for 1 hour. 6 ul of fixed exosome solution was applied to a copper mesh formvar coated with a carbon stabilized grid, absorbed into the grid for 5 minutes, and then accelerated at 80 kV using TEM (H-7650; Hitachi). Analyze iTEM software was used to obtain the image.
  • NanoSight polystyrene latex calibration beads 100 nm and 200 nm were applied for instrument performance check. Exosome size was determined based on light scattering and Brownian motion, and was calculated using the Stokes-Einstein equation with NTA 3.0. NTA software was used to determine the concentration of particles (particles / ml) and particle distribution (nm) and three replicate measurements were performed.
  • TEM showed a isolate containing nano size vesicles and showed a decrease in samples treated with GW4869.
  • PTEN mRNA expression in 344SQ cells was tested 12 hours after treatment with exosomes purified from ApoSQ conditioned medium or conditioned medium.
  • the composition for preventing or treating cancer comprising exosomes derived from apoptosis cells reaches cancer cells, inhibits epithelial-mesenchymal cell conversion in cancer cells, and inhibits cancer cell invasion to prevent or treat cancer metastasis. Imply an excellent effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pour la prévention ou le traitement du cancer, comprenant des exosomes dérivés de cellules apoptotiques ; une utilisation de celle-ci ; et une méthode de traitement du cancer faisant appel à celle-ci. Une composition d'exosomes selon la présente invention est absorbée par les cellules cancéreuses, supprime la transition épithélio-mésenchymateuse dans les cellules cancéreuses, et supprime l'invasion des cellules cancéreuses, présentant ainsi un excellent effet de prévention ou de traitement du cancer.
PCT/KR2019/007379 2018-08-06 2019-06-19 Composition pour la prévention ou le traitement du cancer, comprenant un exosome dérivé de macrophages de suppression de cellules apoptotiques Ceased WO2020032379A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180091437 2018-08-06
KR10-2018-0091437 2018-08-06

Publications (1)

Publication Number Publication Date
WO2020032379A1 true WO2020032379A1 (fr) 2020-02-13

Family

ID=69415253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/007379 Ceased WO2020032379A1 (fr) 2018-08-06 2019-06-19 Composition pour la prévention ou le traitement du cancer, comprenant un exosome dérivé de macrophages de suppression de cellules apoptotiques

Country Status (2)

Country Link
KR (1) KR20200016163A (fr)
WO (1) WO2020032379A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112773775A (zh) * 2021-01-13 2021-05-11 广东药科大学 一种负载去甲斑蝥素外泌体的制备方法及其应用
CN116196332A (zh) * 2021-11-30 2023-06-02 上海交通大学医学院附属第九人民医院 凋亡小体在制备治疗脓毒血症产品中的应用
EP4309660A1 (fr) * 2022-07-18 2024-01-24 Lietuvos Sveikatos Mokslu Universitetas Vésicules extracellulaires et particules à partir de cellules immunitaires pour fournir une activité anticancéreuse
CN119074959A (zh) * 2024-11-06 2024-12-06 广东医科大学附属医院 巨噬细胞膜囊泡修饰的丹参外泌体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160346334A1 (en) * 2014-02-05 2016-12-01 Stc.Unm Exosomes as a therapeutic for cancer
US20170143812A1 (en) * 2015-11-20 2017-05-25 Therapeutic Solutions International, Inc. Exosome mediated innate and adaptive immune stimulation for treatment of cancer
KR20170092095A (ko) * 2016-02-01 2017-08-10 이화여자대학교 산학협력단 사멸화된 세포를 이용한 암 전이 억제용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160346334A1 (en) * 2014-02-05 2016-12-01 Stc.Unm Exosomes as a therapeutic for cancer
US20170143812A1 (en) * 2015-11-20 2017-05-25 Therapeutic Solutions International, Inc. Exosome mediated innate and adaptive immune stimulation for treatment of cancer
KR20170092095A (ko) * 2016-02-01 2017-08-10 이화여자대학교 산학협력단 사멸화된 세포를 이용한 암 전이 억제용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM, Y.-B. ET AL: "Programming of macrophages by apoptotic cancer cells inhibits cancer progression through exosomal PTEN and PPARy ligands", 10 November 2017 (2017-11-10), pages 1 - 75, XP055686150, Retrieved from the Internet <URL:https://www.biorxiv.org/content/biorxiv/early/2017/11/10/217562.full.pdf> DOI: 10.1101/217562 *
YOON, Y.-S.: "Macrophages programmed by apoptotic cells inhibit epithelial-mesenchymal transition in lung alveolar epithelial cells via PGE 2, PGD 2, and HGF", SCIENTIFIC REPORTS, vol. 6, no. 1, 20992, 15 February 2016 (2016-02-15), pages 1 - 18, XP055686154, ISSN: 2045-2322, DOI: 10.1038/srep20992 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112773775A (zh) * 2021-01-13 2021-05-11 广东药科大学 一种负载去甲斑蝥素外泌体的制备方法及其应用
CN116196332A (zh) * 2021-11-30 2023-06-02 上海交通大学医学院附属第九人民医院 凋亡小体在制备治疗脓毒血症产品中的应用
EP4309660A1 (fr) * 2022-07-18 2024-01-24 Lietuvos Sveikatos Mokslu Universitetas Vésicules extracellulaires et particules à partir de cellules immunitaires pour fournir une activité anticancéreuse
WO2024018359A1 (fr) * 2022-07-18 2024-01-25 Lietuvos Sveikatos Mokslu Universitetas Vésicules et particules extracellulaires provenant de cellules immunitaires pour la fourniture d'une activité anticancéreuse
CN119074959A (zh) * 2024-11-06 2024-12-06 广东医科大学附属医院 巨噬细胞膜囊泡修饰的丹参外泌体及其制备方法和应用

Also Published As

Publication number Publication date
KR20200016163A (ko) 2020-02-14

Similar Documents

Publication Publication Date Title
WO2020032379A1 (fr) Composition pour la prévention ou le traitement du cancer, comprenant un exosome dérivé de macrophages de suppression de cellules apoptotiques
Johnson et al. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma
KR101788885B1 (ko) 세포 요법에 사용하기 위한 방법 및 조성물
EP3443966B1 (fr) Composition pour le traitement d&#39;une maladie pulmonaire chronique, comprenant un exosome dérivé de cellules souches traitées par la thrombine
WO2013025042A2 (fr) Composition comprenant des microvésicules issues de cellules souches pour favoriser la neurogenèse
WO2016133254A1 (fr) Nanovésicules dérivées de membrane cellulaire, et leur utilisation
WO2019124666A2 (fr) Composition pharmaceutique comprenant un inhibiteur de l&#39;interleukine-17 et un inhibiteur du facteur de nécrose tumorale alpha en tant que principes actifs pour la prévention ou le traitement d&#39;une maladie pulmonaire inflammatoire neutrophilique
US20190060367A1 (en) 3-d collagen scaffold-generated exosomes and uses thereof
KR20150020113A (ko) mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015142061A1 (fr) Composition pour le traitement d&#39;une maladie inflammatoire du cerveau comprenant un exosome dérivé de cellules souches en tant que principe actif
ITPD20090135A1 (it) Nuovi agenti regolatori dell&#39;attivita&#39; citochinica
JP2011225613A (ja) 腫瘍細胞移動の抑制方法及びこれに用いる薬剤
WO2019107939A1 (fr) Composition pour favoriser la production d&#39;un exosome dérivé d&#39;une cellule souche
EP3964219A1 (fr) Composition pharmaceutique pour le traitement de la septicémie ou du syndrome de réponse inflammatoire systémique, comprenant des mitochondries isolées en tant que principe actif
Stříž et al. Cell–cell contacts with epithelial cells modulate the phenotype of human macrophages
WO2019151744A1 (fr) Nanovésicules dérivées de cellules souches adultes et leur utilisation pour une thérapie ciblée
Zhang et al. Favipiravir ameliorates bleomycin-induced pulmonary fibrosis by reprogramming M1/M2 macrophage polarization
WO2022045813A1 (fr) Composition pharmaceutique pour le traitement, la prévention ou l&#39;inhibition des métastases d&#39;un cancer du poumon, comprenant un exosome en tant que principe actif
Luo et al. [Retracted] Promotion of Differentiating Bone Marrow Mesenchymal Stromal Cells (BMSCs) into Cardiomyocytes via HCN2 and HCN4 Cotransfection
Wu et al. Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Alleviate DSS-induced Inflammatory Bowel Disease in mice through Inhibiting Intestinal Epithelial Cell Pyroptosis via Delivery of TSG-6
WO2014051338A2 (fr) Composition pharmaceutique destinée à être utilisée pour la prévention ou le traitement, comprenant une cellule mononuclée de sang périphérique comme principe actif
KR20200102358A (ko) 수지상세포로의 분화 유도용 조성물
CN106959373B (zh) 干扰素-γ作为咳嗽药物靶点的用途
Huang et al. Combination of Evodiamine with Berberine reveals a Regulatory Effect on the phenotypic transition of Colon epithelial cells Induced by CCD-18Co
Anbeek Investigating human milk extracellular vesicles as therapeutic agents: a study on their efficacy in in vitro hit models of premature encephalopathy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19847051

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19847051

Country of ref document: EP

Kind code of ref document: A1